Loading…
Chinese vaccine and biologics maker based in Changchun, with a focus on rabies vaccine and blood-plasma products.
Chinese vaccine and biologics maker based in Changchun, with a focus on rabies vaccine and blood-plasma products.
Moat: narrow (regulatory licence). Licensed rabies-vaccine and plasma production base, competing with larger national players.
Headquarters: Changchun, China · Employees: 1,252
Size Changchun BCHT Biotechnology (688276.SS) is a China Health Care company (Biotechnology) with a market value of $1.00B, the 2291st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥16.18 on 6 Nov 2026.
Performance Over six months the shares fell 10.9%, against -10.6% for the median peer and -16.4% for the China market (cap-weighted) — 10th lowest of 20 in its peer set.
Growth Revenue grew 2.5% over the last twelve months (peer median +0.9%); the operating margin is -28.8% (peer median -71.5%).
Valuation It trades at 10.0× enterprise value to sales against a peer median of 7.5× (9th most expensive of 19).
Capital Return on invested capital runs 12.3 points below its cost of capital (10.0% WACC).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥694M | CN¥603M | CN¥1.22B | CN¥1.82B | CN¥1.07B |
| Revenue growth | — | -51% | -33% | +70% | — |
| Gross profit | CN¥530M | CN¥292M | CN¥1.01B | CN¥1.60B | CN¥904M |
| EBITDA | n/a | -CN¥162M | CN¥364M | CN¥641M | CN¥237M |
| Net income | -CN¥200M | -CN¥263M | CN¥232M | CN¥501M | CN¥182M |
| Free cash flow | -CN¥111M | -CN¥180M | -CN¥138M | -CN¥278M | -CN¥292M |
| Capital expenditure | CN¥403M | CN¥406M | CN¥542M | CN¥471M | CN¥291M |
| Total debt | CN¥513M | CN¥265M | CN¥103M | CN¥20.5M | CN¥0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Changchun BCHT Biotechnology 688276.SS | $1.00B | -11% | +2% | -29% | 10.0× | n/a |
| Liaoning Chengda Biotechnology 688739.SS | $1.28B | -10% | -9% | 0% | 2.5× | 8.8% |
| Hualan Biological Engineering 002007.SZ | $3.37B | -15% | -11% | 17% | 5.6× | 16.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688276.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.6% | -3.2% | 7th lowest of 21 |
| 6-month return | -10.9% | -10.6% | 10th lowest of 20 |
| Distance from 52-week high | -33.9% | -41.7% | 7th highest of 21 |
| Revenue growth (TTM) | +2.5% | +0.9% | 7th highest of 17 |
| Operating margin | -28.8% | -71.5% | 9th highest of 19 |
| EV / Sales | 10.0× | 7.5× | 9th most expensive of 19 |
| ROIC minus cost of capital | -12.3 pp | -11.3 pp | 6th lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Changchun BCHT Biotechnology 688276.SS | China | $1.00B | -11% | +2% | -29% | 10.0× | n/a | n/a |
| Chengdu Kanghua Biological Products Co. Td Class 1 300841.SZ | China | $995M | -11% | 0% | 22% | 4.7× | 11.1% | +2.3% |
| Innovita Biological Technology 688253.SS | China | $1.02B | -4% | -28% | 11% | 16.3× | 42.9% | -16.6% |
| Alto Neuroscience ANRO | United States | $987M | +4% | n/a | n/a | n/a | n/a | n/a |
| Verastem VSTM | United States | $1.02B | +72% | +3,996% | -183% | 11.1× | n/a | n/a |
| China Animal Husbandry Industry 600195.SS | China | $960M | -17% | +1% | 2% | 1.4× | 6.6% | +4.4% |
| Jade Biosciences JBIO | United States | $958M | -42% | n/a | n/a | n/a | n/a | n/a |
| Janux Therapeutics JANX | United States | $1.08B | +24% | +5,367% | -598% | 5.3× | n/a | n/a |
| Nanjing Leads Biolabs 9887.HK | Hong Kong | $927M | -54% | n/a | -108% | 26.5× | n/a | n/a |
| Odyssey Therapeutics ODTX | United States | $924M | n/a | -33% | -5,415% | 208.9× | n/a | n/a |
| Inventiva IVA.PA | France | $912M | -29% | -100% | -307,063% | 14,560.9× | n/a | n/a |
| Daan Gene 002030.SZ | China | $1.11B | -9% | +1% | -81% | 8.4× | 5.7% | -32.3% |
| Monte Rosa Therapeutics GLUE | United States | $902M | -45% | -84% | -633% | 11.1× | n/a | n/a |
| Oxford BioMedica OXB.L | United Kingdom | $892M | -14% | +16% | -18% | 4.3× | n/a | n/a |
| Guangzhou Wondfo Biotech 300482.SZ | China | $1.14B | -10% | -24% | -2% | 3.2× | 16.4% | -5.8% |
| GNI 2160.T | Japan | $866M | -29% | +10% | -24% | 5.7× | n/a | n/a |
| MeiraGTx MGTX | United States | $864M | -8% | +948% | 46% | 2.1× | -9.9% | +39.2% |
| Rapport Therapeutics RAPP | United States | $1.17B | -36% | n/a | -838% | 39.3× | n/a | n/a |
| Syndax Pharmaceuticals SNDX | United States | $859M | -56% | +160% | -62% | 3.5× | n/a | n/a |
| Peptidream 4587.T | Japan | $856M | -10% | +1% | -25% | 6.6× | n/a | n/a |
| Prime Medicine PRME | United States | $843M | +45% | -18% | -4,825% | 211.3× | n/a | n/a |